Baidu Shares Surge After Official Launch of Advanced Ernie 5.0 AI Model 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
FAA Says It Is Not Blocking Boeing 737 MAX 7 and MAX 10 Certification 
Elon Musk Shares Bold Vision for AI, Robots, and Space at Davos 
Valero Makes First Venezuelan Crude Purchase Under New U.S.-Caracas Deal 
Walmart to Cut PhonePe Stake in IPO as Tiger Global and Microsoft Exit 
BitGo IPO Prices Above Range, Raises $212.8M in Landmark Crypto Market Debut 
Morgan Stanley Flags High Volatility Ahead for Tesla Stock on Robotaxi and AI Updates 
Apple China Holiday Sale Offers Discounts Up to 1,000 Yuan on Popular Devices 
OpenAI Launches Stargate Community Plan to Offset Energy Costs and Support Local Power Infrastructure 
FSU Criticizes ANZ Over Suncorp Bank Job Cuts Amid Post-Acquisition Commitments 
Global DRAM Chip Shortage Puts Automakers Under New Cost and Supply Pressure 
Nintendo Stock Jumps as Switch 2 Becomes Best-Selling Console in the U.S. in 2025 
United Airlines Posts Record Q4 Revenue as Premium Demand Lifts Earnings 
Trump Signs Executive Order to Limit Wall Street Investment in Single-Family Homes 
SoftBank Shares Surge as AI Optimism Lifts Asian Tech Stocks 
CAMBRIDGE, Mass., May 04, 2017 -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS), today announced its first quarter 2017 financial results and corporate highlights conference call and live webcast scheduled for Tuesday, May 9, 2017 at 5:30 p.m. EDT.
The live call may be accessed by dialing (877) 851-3834 for domestic callers or +1 (631) 291-4595 for international callers, and referencing conference ID number 18530851. A live audio webcast of the conference call will be available online from the Investors & Media section of Voyager’s website at www.voyagertherapeutics.com. The webcast will be archived for 30 days.
About Voyager Therapeutics
Voyager Therapeutics is a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the CNS. Voyager is committed to advancing the field of AAV gene therapy through innovation and investment in vector engineering and optimization, manufacturing and dosing and delivery techniques. The Company’s pipeline focuses on severe CNS diseases in need of effective new therapies, including advanced Parkinson’s disease, a monogenic form of ALS, Huntington’s disease, Friedreich’s ataxia, frontotemporal dementia, Alzheimer’s disease and severe, chronic pain. Voyager has broad strategic collaborations with Sanofi Genzyme, the specialty care global business unit of Sanofi, and the University of Massachusetts Medical School. Founded by scientific and clinical leaders in the fields of AAV gene therapy, expressed RNA interference and neuroscience, Voyager Therapeutics is headquartered in Cambridge, Massachusetts. For more information, please visit www.voyagertherapeutics.com. Follow Voyager on LinkedIn.
Investor Relations: Matt Osborne Head of Investor Relations & Corporate Communications 857-259-5353 [email protected] Media: Katie Engleman Pure Communications, Inc. 910-509-3977 [email protected]
